DATA SHEET 1 CLEXANE AND CLEXANE FORTE 2 …

NEW ZEALAND DATA SHEET - Medsafe

Treatment of recurrent, platinum-resistant disease: 10 mg/kg body weight given once every 2 weeks when administered in combination with one of …

  Sheet, Data, Zealand, New zealand data sheet

Madopar (levodopa) Data Sheet (DS) - Medsafe

MADOPAR 160202 1 Data Sheet MADOPAR® Levodopa + benserazide Capsules 62.5, 125 and 250; dispersible tablet 62.5; HBS modified-release capsule 125

  Levodopa, Dispersible

Section 1: Legislation - Medsafe Home Page

Section 2: Overview of Regulation of Clinical Trials in New Zealand . Section summary Under Section 30 of the Medicines Act 1981, approval from the Director-General of

  Section, Clinical, Legislation, Section 1

Section 1: Legislation relating to the labelling - …

Part 5, Ed 1.6 Page 2 of 18 . Section 1: Legislation relating to the labelling of medicines and related products Section summary This section lists the legislation regulating the labelling of medicines and related products.

  Section, Relating, Legislation, Labelling, Section 1, Legislation relating to the labelling

NEW ZEALAND DATA SHEET VERMOX® - …

NEW ZEALAND DATA SHEET VERMOX® Vermox® Page 2 of 7 For control of enterobiasis Adults and children 2-12 years: 1 Vermox tablet (100 mg) or 5 mL of suspension (100 mg) is given.

Guideline on the Regulation of Therapeutic …

Guideline on the Regulation of Therapeutic Products in New Zealand Part 10: Requirements for information for prescribers and consumers Edition 7.0

  Guidelines, Product, Regulations, Therapeutic, Guideline on the regulation of therapeutic, Guideline on the regulation of therapeutic products in

Clonazepam: oral drops (2.5 mg/ml); injection (1 mg).

2. you have severe and chronic lung disease 3. you have severe liver disease 4. you have an addiction to drugs or alcohol 5. the package is torn or shows signs of tampering

  Clonazepam

NEW ZEALAND DATA SHEET - Medsafe

NEW ZEALAND DATA SHEET 5 Hypnovel 170717 Medical history of alcohol or drug abuse Hypnovel should be avoided in patients with a medical history of alcohol or drug abuse.

  Drug

SCHEDULE OF FEES (effective from 1 July 2018)

Page 1 of 10. SCHEDULE OF FEES (effective from 1 July 2018) • All fees listed are GST inclusive. • More detailed descriptions of the type of application or change to which a fee applies can be

  Schedule, Effective, Fees, Schedule of fees

Nortriptyline (as hydrochloride) 10 mg and 25 mg Tablets

1 Nortriptyline NRIM 09052013 NEW ZEALAND DATA SHEET Nortriptyline NRIM . Nortriptyline (as hydrochloride) 10 mg and 25 mg Tablets . This product may not be interchangeable with similar products on the New Zealand market

ESPEN Guidelines on Enteral Nutrition: Adult Renal Failure

Extracorporeal treatment induces increased losses of micronutrients which should be supplemented. 1.7 Monitor micronutrient status because excessive supplementation may result in toxicity. C 1.7 In ICU patients with ARF, the electrolyte content of most 1500–2000kcal enteral formulae is usually adequate. However, requirements can differ and have

  Guidelines, Treatment, Nutrition, Adults, Learn, Enteral, Espen, Espen guidelines on enteral nutrition, Adult renal

Guideline for Anticoagulation and Prophylaxis Using Low ...

haemodialysis and treatment of acute deep vein thrombosis (DVT). Prevention of thrombosis in extracorporeal circulation during haemodialysis. Treatment of established DVT. Extended treatment of symptomatic VTE (proximal DVT and/or pulmonary embolism) to reduce the recurrence of VTE in patients with solid tumour cancers.

  Guidelines, Using, Treatment, Prophylaxis, Anticoagulation, Haemodialysis, Guideline for anticoagulation and prophylaxis using low

Neuropathic Pain Treatment Guidelines

• Chronic neuropathic pain is a long-term condition and the aim of treatment is management rather than cure • Important to explain implications and chronicity to the patient and the importance of compliance with treatment • Effective treatment is considered as 30% reduction in pain score and/or improved function

  Treatment

Guideline - Treatment of tuberculosis in renal disease

Guideline – Treatment of tuberculosis in renal disease Version 3.0 6 * When daily doses are due on haemodialysis days, it is advisable to administer drugs after the dialysis session—afternoon or evening—to minimise the removal of the active drug by dialysis. Cycloserine

  Treatment, Haemodialysis

Clinical Practice Guideline Haemodialysis

There are a few changes in scope, for example dialysis water treatment is now covered in another guideline, as are many aspects of dialysis, including: Planning, initiation & withdrawal of Renal Replacement Therapy Vascular Access for …

  Treatment, Haemodialysis

Heparin Induced Thrombocytopenia, Diagnosis and …

or Rivaroxaban for the treatment of VTE, for dosing advice, duration and discharge information. ... • Patients with possible diagnosis of HIT requiring surgery or haemodialysis – seek advice from Pharmacy/Haematology Department. NHS GG&C Clinical Haematology HIT Guideline ;

  Treatment, Diagnosis, Induced, Diagnosis and, Thrombocytopenia, Heparin, Haemodialysis, Heparin induced thrombocytopenia

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

Pregabalin is removed effectively from plasma by haemodialysis (50% of drug in 4 hours). For patients receiving haemodialysis, the pregabalin daily dose should be adjusted based on renal function. In addition to the daily dose, a supplementary dose should be given immediately following every 4 hour haemodialysis treatment (see Table 1). > @ (m ...

  Product, Treatment, Summary, Characteristics, Summary of product characteristics, Haemodialysis, Haemodialysis treatment

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

Treatment: The following weight -adjusted dosing regimens are recommended for treatment of infants and children 1 year of age or older: ... Haemodialysis patients 30 mg after each haemodialysis session Peritoneal dialysis patients* 30 mg (suspension or capsules) single dose

  Product, Treatment, Summary, Characteristics, Summary of product characteristics, Haemodialysis

Treatment Guideline - Gloucestershire Hospitals NHS ...

Do not use cation-exchange resins (Calcium Resonium®/ Resonium A®) for the emergency treatment of severe hyperkalaemia. The onset of action is slow (up to five days) and they can cause severe gastrointestinal side-effects. Haemodialysis or haemofiltration are the most effective but invasive treatments for severe resistant hyperkalaemia

  Treatment, Haemodialysis

Oseltamivir (Tamiflu ) Doses in Children

Treatment with Oseltamivir (Tamiflu®) or Zanamivir (Relenza®) should be limited to: o All children with suspected influenza who are severely unwell (who will usually be admitted) including those under 1 year of age. Children < 5 yrs old, particularly those < …

  Treatment